16.30 USD
↗ 0.20 (1.24%)AT CLOSE (03:59 PM EST)
Ultragenyx Pharmaceutical Inc.
RARENASDAQ • USD
16.31
↗ 0.01 (0.06%)
POST MARKET (AS OF 04:10 PM EST)
Post Market
AS OF 04:10 PM EST
16.31
↗ 0.01 (0.06%)
Market: OPEN
Ultragenyx Pharmaceutical Inc. (RARE) trades at $16.31 per share. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (201.4%) and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest RARE is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Nov 2, 2026.
Open?$16.29
High?$16.44
Low?$15.85
Prev. Close?$16.10
Volume?4.8M
Avg. Volume?3.9M
VWAP?$16.26
Rel. Volume?1.24x
Bid / Ask
Bid?$13.34 × 100
Ask?$20.07 × 100
Spread?$6.73
Midpoint?$16.71
Valuation & Ratios
Market Cap?1.6B
Shares Out?98.6M
Float?93.5M
Float %?94.9%
P/E Ratio?N/A
P/B Ratio?-5.45
EPS?-$5.94
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Employees
1.4K
Market Cap
1.6B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-01-31
Address
60 LEVERONI COURT
NOVATO, CA 94949
Phone: 415-483-8800
NOVATO, CA 94949
Phone: 415-483-8800
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?0
Momentum?50
Short Sent.?51
Piotroski F-Score?2/9Weak
Altman Z-Score?-5.28Distress
Confidence?62%Moderate
Short InterestSqueeze Risk
Short % of Float?21.54%Squeeze Risk
Short Interest?20.1M
Days to Cover?5.2
Free Float93.5M
Avg Daily Volume3.9M
Settlement Date2026-10-15
Financial Health
Current Ratio?1.73Adequate
Quick Ratio?1.56Adequate
Cash Ratio?0.36Low
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-5.45CHEAP▾
S&P97
P/S?2.21CHEAP▾
Peers100
S&P62
P/FCF?N/A▾
EV/EBITDA?-3.0CHEAP▾
S&P97
EV/Sales?2.04CHEAP▾
Peers100
S&P74
Returns & Efficiency
ROE?201.4%STRONG▾
Peers50
S&P97
ROA?-46.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-489468000
Enterprise Value?$1.5B
Fundamentals ratios updated end of day